Quest Diagnostics (DGX) to Release Earnings on Tuesday

Key Points

• Upcoming Q1 2026 results are scheduled before the open on Tuesday, April 21; analysts expect $2.37 EPS and $2.8266B revenue, and Quest has guided FY2026 to $9.45–$9.65 EPS.
• Quest increased its quarterly dividend to $0.86 from $0.80, payable April 20 to holders of record April 6, implying a 1.8% yield and a ~39.3% payout ratio.
• The board authorized a $1.0B share repurchase program (about 4.7% of shares), and the company recently beat Q4 estimates with $2.42 EPS and 7.1% year‑over‑year revenue growth.

Quest Diagnostics (NYSE:DGX - Get Free Report) will likely be posting its Q1 2026 results before the market opens on Tuesday, April 21st. Analysts expect Quest Diagnostics to post earnings of $2.37 per share and revenue of $2.8266 billion for the quarter. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, April 21, 2026 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.35 by $0.07. The company had revenue of $2.81 billion during the quarter, compared to analysts' expectations of $2.75 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. Quest Diagnostics's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the business earned $2.23 EPS. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Stock Up 0.7%

DGX stock opened at $192.82 on Tuesday. The firm has a 50 day moving average of $200.13 and a 200 day moving average of $188.58. The stock has a market capitalization of $21.34 billion, a PE ratio of 22.04, a price-to-earnings-growth ratio of 2.47 and a beta of 0.66. The company has a quick ratio of 0.96, a current ratio of 1.04 and a debt-to-equity ratio of 0.72. Quest Diagnostics has a 52 week low of $160.02 and a 52 week high of $213.50.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be paid a $0.86 dividend. This is a boost from Quest Diagnostics's previous quarterly dividend of $0.80. The ex-dividend date is Monday, April 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.8%. Quest Diagnostics's dividend payout ratio (DPR) is 39.31%.

Quest Diagnostics announced that its board has approved a share repurchase program on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 4.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Evercore set a $210.00 target price on shares of Quest Diagnostics in a research note on Wednesday, April 8th. Robert W. Baird set a $219.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, February 11th. Barclays lifted their price objective on shares of Quest Diagnostics from $210.00 to $225.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Jefferies Financial Group lifted their price objective on shares of Quest Diagnostics from $215.00 to $220.00 and gave the company a "buy" rating in a research note on Tuesday, February 10th. Finally, Truist Financial lifted their price objective on shares of Quest Diagnostics from $205.00 to $220.00 and gave the company a "hold" rating in a research note on Wednesday, February 11th. Seven analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $210.69.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Patrick Plewman sold 2,855 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $588,729.55. Following the completion of the transaction, the senior vice president directly owned 15,198 shares of the company's stock, valued at $3,133,979.58. The trade was a 15.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael E. Prevoznik sold 3,878 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $799,682.38. Following the transaction, the senior vice president directly owned 37,557 shares of the company's stock, valued at approximately $7,744,628.97. This trade represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 24,083 shares of company stock valued at $4,945,262. 8.16% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Quest Diagnostics

Several institutional investors have recently made changes to their positions in the company. Moneta Group Investment Advisors LLC increased its holdings in shares of Quest Diagnostics by 3.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company's stock valued at $241,000 after purchasing an additional 50 shares in the last quarter. Ossiam increased its holdings in shares of Quest Diagnostics by 6.1% during the 3rd quarter. Ossiam now owns 1,059 shares of the medical research company's stock valued at $202,000 after purchasing an additional 61 shares in the last quarter. Brown Advisory Inc. increased its holdings in shares of Quest Diagnostics by 1.0% during the 4th quarter. Brown Advisory Inc. now owns 7,287 shares of the medical research company's stock valued at $1,265,000 after purchasing an additional 71 shares in the last quarter. Advisory Services Network LLC increased its holdings in shares of Quest Diagnostics by 2.3% during the 4th quarter. Advisory Services Network LLC now owns 3,518 shares of the medical research company's stock valued at $611,000 after purchasing an additional 80 shares in the last quarter. Finally, Meeder Advisory Services Inc. increased its holdings in shares of Quest Diagnostics by 2.4% during the 4th quarter. Meeder Advisory Services Inc. now owns 3,505 shares of the medical research company's stock valued at $608,000 after purchasing an additional 82 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.